# reload+after+2024-01-23 10:44:30.257833
address1§11 Hurley Street
city§Cambridge
state§MA
zip§02141
country§United States
phone§617 401 9000
website§https://www.editasmedicine.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
fullTimeEmployees§226
companyOfficers§[{'maxAge': 1, 'name': "Dr. Gilmore  O'Neill", 'age': 59, 'title': 'President, CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 815371, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Baisong  Mei M.D., Ph.D.', 'title': 'Senior VP & Chief Medical Officer', 'fiscalYear': 2022, 'totalPay': 386989, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Feng  Zhang Ph.D.', 'title': 'Co-Founder & Scientific Advisory Board Member', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. George McDonald Church Ph.D.', 'age': 69, 'title': 'Co-Founder & Scientific Advisory Board Member', 'yearBorn': 1954, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. J. Keith Joung M.D., Ph.D.', 'title': 'Co-Founder & Scientific Advisory Board Member', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David R. Liu Ph.D.', 'title': 'Co-Founder & Scientific Advisory Board Member', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Harry R. Gill III', 'age': 62, 'title': 'Senior Vice President of Operations', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Linda C. Burkly Ph.D.', 'title': 'Executive VP & Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Cristi  Barnett', 'title': 'Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Charlene  Stern J.D., Ph.D.', 'title': 'Executive VP & General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§4
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.891
priceToSalesTrailing12Months§30.167164
currency§USD
dateShortInterest§1702598400
forwardEps§-2.38
pegRatio§-2.4
exchange§NMS
quoteType§EQUITY
shortName§Editas Medicine, Inc.
longName§Editas Medicine, Inc.
firstTradeDateEpochUtc§1454509800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§93762d80-2eed-34b3-a1c5-9d1d46b35248
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§7.0
targetMeanPrice§14.67
targetMedianPrice§15.0
recommendationMean§2.4
recommendationKey§buy
numberOfAnalystOpinions§15
quickRatio§6.007
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
